Şunu aradınız:: repolarization (İngilizce - Maltaca)

effects on cardiac repolarization
effetti fuq ir-ripolarizzazzjoni kardijaka

qt-prolonging substances or known to increase the risk of repolarization disorders
sustanzi li jtawwlu l-qt jew li huma magħrufin li jżidu r-riskju ta' disturbi ta' ripolarizzazzjoni

no effect was observed of amifampridine phosphate on cardiac repolarization as assessed using the qtc interval.
l-ebda effett ta’ amifampridine phosphate ma ġie osservat fuq ir- ripolarizzazzjoni kardijaka kif evalwat bl-użu tal-intervall tal-qtc.

no clinically significant changes were shown on heart rate, atrioventricular (av) conduction and cardiac repolarization.
ma ntwera l-ebda tibdil klinikament sinifikanti fuq ir-rata ta’ taħbit tal-qalb, it-trasmissjoni atrijoventrikulari (av) u r-ripolarizzazzjoni fil- qalb.

1 adverse reactions reported in a clinical study to evaluate the effects of amifampridine on cardiac repolarization at a single dose of 30 mg or 60 mg in healthy volunteers.
1 reazzjonijiet avversi rrappurtati fi studju kliniku sabiex jiġu evalwati l-effetti ta’ amifampridine fuq ir-ripolarizzazzjoni kardiiaka wara doża waħda ta’ 30 mg jew 60 mg f’voluntiera b’saħħithom.

dasatinib activity in vitro in herg and purkinje fiber assays suggested a potential for prolongation of cardiac ventricular repolarization (qt interval).
l- attività in vitro ta ’ dasatinib f’ analiżi herg u purkinje fiber issuġġeriet potenzjal għal titwil tar - ripolarizzazzjoni ventrikulari kardijaka (intervall qt).

by blocking potassium channels, fampyra reduces the leakage of ionic current through these channels, thereby prolonging repolarization and thus enhancing action potential formation in demyelinated axons and neurological function.
billi jimblokka l-kanali tal-potassium, fampyra jnaqqas it-tnixxija ta’ kurrent joniku minn ġo dawn il-kanali, u b’hekk itawwal ir-ripolarizzazzjoni u għaldaqstant itejjeb il-formazzjoni potenzjali tal-azzjoni f’demyelinated axons u l-funzjoni newroloġika.

nevertheless, patients with cardiac disease, co-medicated with other qt-prolonging medicinal products or known to increase the risk of repolarization disorders, or co-medicated with medicinal products that significantly increase pitolisant cmax and auc ratio (see section 4.5) or patients with severe renal or moderate hepatic impairment (see section 4.4) should be carefully monitored (see section 4.5).
madankollu, pazjenti b'mard kardijaku, komedikati bi prodotti mediċinali oħra li jtawwlu l- qt jew magħrufa li jżidu r-riskju ta' disturbi ta' ripolarizzazzjoni, jew komedikati bi prodotti mediċinali li jżidu b'mod sinifikanti l-proporzjon ta' cmax u auc ta' pitolisant (ara sezzjoni 4.5) jew pazjenti b'indeboliment tal-kliewi sever jew tal-fwied moderat (ara sezzjoni 4.4) għandhom jiġu sorveljati b'attenzjoni (ara sezzjoni 4.5).